COVID-19: vaccination vs. hospitalization
Authors:
- 4 January 2022
- journal article
- research article
- Published by Springer Nature in Infection
- Vol. 50 (3) , 747-752
Abstract
Objective Vaccination is the most efficient way to control the coronavirus disease 2019 (COVID-19) pandemic, but vaccination rates remain below the target level in most countries. This multicenter study aimed to evaluate the vaccination status of hospitalized patients and compare two different booster vaccine protocols. Setting Inoculation in Turkey began in mid-January 2021. Sinovac was the only available vaccine until April 2021, when BioNTech was added. At the beginning of July 2021, the government offered a third booster dose to healthcare workers and people aged > 50 years who had received the two doses of Sinovac. Of the participants who received a booster, most chose BioNTech as the third dose. Methods We collected data from 25 hospitals in 16 cities. Patients hospitalized between August 1 and 10, 2021, were included and categorized into eight groups according to their vaccination status. Results We identified 1401 patients, of which 529 (37.7%) were admitted to intensive care units. Nearly half (47.8%) of the patients were not vaccinated, and those with two doses of Sinovac formed the second largest group (32.9%). Hospitalizations were lower in the group which received 2 doses of Sinovac and a booster dose of BioNTech than in the group which received 3 doses of Sinovac. Conclusion Effective vaccinations decreased COVID-19-related hospitalizations. The efficacy after two doses of Sinovac may decrease over time; however, it may be enhanced by adding a booster dose. Moreover, unvaccinated patients may be persuaded to undergo vaccination.Keywords
This publication has 11 references indexed in Scilit:
- Effectiveness of an Inactivated SARS-CoV-2 Vaccine in ChileNew England Journal of Medicine, 2021
- COVID vaccines protect against Delta, but their effectiveness wanesNature, 2021
- Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escapeNature Reviews Immunology, 2021
- Review of COVID-19 vaccine subtypes, efficacy and geographical distributionsPostgraduate Medical Journal, 2021
- COVID vaccine boosters: the most important questionsNature, 2021
- Reduced mortality rate after coronavac vaccine among healthcare workersJournal of Infection, 2021
- Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in TurkeyThe Lancet, 2021
- Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance dataThe Lancet, 2021
- Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in RussiaThe Lancet, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020